Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 1
1985 3
1986 3
1987 5
1988 3
1989 4
1990 1
1991 3
1992 3
1993 3
1994 1
1995 2
1996 1
1997 4
1998 2
1999 2
2000 2
2001 3
2002 1
2003 4
2004 10
2005 4
2006 2
2007 9
2008 10
2009 9
2010 7
2011 11
2012 7
2013 8
2014 4
2015 14
2016 6
2017 4
2018 10
2019 3
2020 5
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Free article. Clinical Trial.
Cardiovascular toxicity of anti-angiogenic drugs.
des Guetz G, Uzzan B, Chouahnia K, Morère JF. des Guetz G, et al. Among authors: morere jf. Target Oncol. 2011 Dec;6(4):197-202. doi: 10.1007/s11523-011-0204-7. Epub 2011 Nov 25. Target Oncol. 2011. PMID: 22116787 Review.
Anaphylaxis after oxaliplatin.
Médioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL. Médioni J, et al. Among authors: morere jf. Ann Oncol. 1999 May;10(5):610. doi: 10.1023/a:1026498513593. Ann Oncol. 1999. PMID: 10416017 Free article. No abstract available.
Melanoma: a new landmark in targeted oncology.
Morère JF. Morère JF. Target Oncol. 2011 Sep;6(3):131. doi: 10.1007/s11523-011-0195-4. Epub 2011 Aug 20. Target Oncol. 2011. PMID: 21858472 No abstract available.
[Anemia and lung cancer].
Bréchot JM, Morère JF. Bréchot JM, et al. Among authors: morere jf. Rev Pneumol Clin. 2008 Apr;64(2):81-4. doi: 10.1016/j.pneumo.2008.04.002. Epub 2008 Jun 5. Rev Pneumol Clin. 2008. PMID: 18589288 Review. French.
Prostate cancer screening: contrasting trends.
Eisinger F, Morère JF, Touboul C, Pivot X, Coscas Y, Blay JY, Lhomel C, Viguier J. Eisinger F, et al. Among authors: morere jf. Cancer Causes Control. 2015 Jun;26(6):949-52. doi: 10.1007/s10552-015-0573-9. Epub 2015 Mar 31. Cancer Causes Control. 2015. PMID: 25822574
169 results